About Zogenix, Inc. (ZGNX) — Dividend Analysis 2026
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
Is ZGNX a good dividend investment in 2026?
ZGNX offers a 7.50% forward yield with a 50% payout ratio. Strand Safety Score: 15/100 (Critical Risk). The 5-year dividend CAGR of 0% is modest — investors should weigh current income against growth alternatives.
ZGNX DRIP calculator — what's the difference?
With DRIP on a $10,000 investment over 10 years, your ZGNX portfolio grows to $181.9K vs $153.0K without reinvestment. This is the compound interest effect in action.
ZGNX dividend growth history & forecast
ZGNX has grown its dividend by 0% over the last year and 0% annually over 5 years. At this pace, an investor who holds for 10+ years will see their yield on cost grow substantially above the current 7.50%.
Company generates negative FCF ($-185M) — borrowing to pay dividends
Debt Leverage0.0× Debt/EBITDA
0 / 30 pts
0/30
Company not generating EBITDA — debt servicing risk is elevated
Earnings Momentum-0.2B → -0.2B → -0.4B
15 / 30 pts
15/30
Net income grew in the latest year — positive but trend is unconfirmed
OVERALL ASSESSMENT
High risk of dividend cut — weak fundamentals across multiple factors.
STRAND SCORE
15
/100
Strand Safety Score™ is proprietary to DividendFlow. Inputs: FCF, Debt/EBITDA, Net Income from SEC filings via FMP. Not financial advice. N/A for ETFs, pre-revenue companies, and tickers without income statements.
🌍 ZGNX Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold ZGNX.
Gross yield
7.50%
Tax rate
15.00%
After-tax yield
6.38%
Real yield (−CPI)
3.58%
Account/Country
Tax Rate
After-tax Yield
Real Yield
$10K Annual Income
🇺🇸 Roth IRA / 401k
0%
7.50%
4.70%
$750 / yr
🇺🇸 US Taxable (15%) ✓
15%
6.38%
3.58%
$638 / yr
🇺🇸 US Taxable (20%)
20%
6.00%
3.20%
$600 / yr
🇬🇧 UK ISA
0%
7.50%
4.70%
$750 / yr
🇬🇧 UK Taxable
8.75%
6.84%
4.04%
$684 / yr
🇨🇦 TFSA
0%
7.50%
4.70%
$750 / yr
🇨🇦 CA Taxable
25%
5.63%
2.83%
$563 / yr
🇦🇺 Super (pension)
15%
6.38%
3.58%
$638 / yr
🇦🇺 AU Taxable
30%
5.25%
2.45%
$525 / yr
🇩🇪 DE Taxable
26.375%
5.52%
2.72%
$552 / yr
🇫🇷 FR Taxable
30%
5.25%
2.45%
$525 / yr
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 ZGNX Income Goal & Break-Even
Dividend Break-Even
16yr
Years for dividends to fully repay your ZGNX investment of $26.68/share (🇺🇸 US Taxable (15%) · 15.00% tax)
$10K invested · 10 Years
Dividends earned (DRIP)
$7.2K
Lost to inflation (2.8% CPI)
−$2.5K
Real purchasing power gain
$4.7K
12-month CPI (US BLS via FMP economic-indicators).
How much do I need to invest in ZGNX for:
Shares needed
14,118
Capital required
$376,668
Monthly income
$2,000
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 ZGNX Dividend Payment Schedule
ZGNX pays quarterly — 4 times per year. Next ex-div: TBD.
Jan
Feb
Mar
💰
Apr
May
Jun
💰
Jul
Aug
Sep
💰
Oct
Nov
Dec
💰
10 shares
$4.25 / payment
$17.00 / year after tax
100 shares
$42.50 / payment
$170.00 / year after tax
1,000 shares
$425.00 / payment
$1700.00 / year after tax
📊 ZGNX vs Healthcare Benchmarks
How ZGNX compares to typical Healthcare averages.
Benchmark: Healthcare
Dividend Yield▲+4.70% vs sectorBetter
ZGNX
7.50%
avg
2.80%
5Y Dividend CAGR▼-6.80% vs sectorBelow avg
ZGNX
0.00%
avg
6.80%
Payout Ratio▲-5.00% vs sectorBetter
ZGNX
50.00%
avg
55.00%
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for ZGNX sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ ZGNX Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
Insider
Title
Type
Date
Shares
Price
Total Value
BREITMEYER JAMES B
director
D-Return
2022-03-07
6,250
$15.52
$97.0K
BREITMEYER JAMES B
director
D-Return
2022-03-07
20,000
$12.75
$255.0K
BREITMEYER JAMES B
director
U-Tender
2022-03-07
1,250
$26.00
$32.5K
BREITMEYER JAMES B
director
D-Return
2022-03-07
9,375
$24.56
$230.3K
BREITMEYER JAMES B
director
D-Return
2022-03-07
10,000
$8.99
$89.9K
BREITMEYER JAMES B
director
D-Return
2022-03-07
22,000
$17.83
$392.3K
BREITMEYER JAMES B
director
D-Return
2022-03-07
9,000
$12.80
$115.2K
Stutts Mary E.
director
D-Return
2022-03-07
22,000
$17.83
$392.3K
Stutts Mary E.
director
D-Return
2022-03-07
20,000
$22.82
$456.4K
BOCK LOUIS C
director
D-Return
2022-03-07
20,000
$12.75
$255.0K
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
🎯
Analyst Price Target
Wall Street consensus
Current Price
$26.68
Analyst Target
$26.00
Upside / Downside
-2.5%
Range
$26.00 – $26.00
💡 If ZGNX reaches the analyst target of $26.00, investors buying today at $26.68 would see an effective yield of 7.69% on shares purchased at target price — vs 7.50% at current price.
Analyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
🌍
Geographic Revenue Breakdown
Where ZGNX earns its money
UNITED STATES88%
Europe12%
Revenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
📊 About This Data
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the ZGNX dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →